Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
第3相
完了
NCT03517449
| 対象疾患 | Endometrial Neoplasms |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Eisai Inc. |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 827 名 |
|---|
| 介入（薬剤） | Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin |
|---|
| 開始日 | 2018年6月11日 |
|---|
| 完了日 | 2022年3月1日 |
|---|
| 結果公開日 | 2021年11月17日 |
|---|
概要
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
Up to approximately 27 months · Months
| Lenvatinib 20 mg + Pembrolizumab 200 mg | 6.6 ± 5.6 Months |
|---|
| Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | 3.8 ± 3.6 Months |
|---|
| p-value | < 0.0001 |
|---|
| Hazard Ratio (HR) | 0.60 (95% CI 0.50–0.72) |
|---|
PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants
Up to approximately 27 months · Months
| Lenvatinib 20 mg + Pembrolizumab 200 mg | 7.2 ± 5.7 Months |
|---|
| Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel | 3.8 ± 3.6 Months |
|---|
| p-value | < 0.0001 |
|---|
| Hazard Ratio (HR) | 0.56 (95% CI 0.47–0.66) |
|---|
Overall Survival (OS) in pMMR Participants
Up to approximately 43 months · Months
| Lenvatinib 20 mg + Pembrolizumab 200 mg | 18.0 Months |
|---|
| Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel | 12.2 Months |
|---|
| p-value | < 0.0001 |
|---|
| Hazard Ratio (HR) | 0.70 (95% CI 0.58–0.83) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。